India, May 13 -- CytoDyn Inc. (CYDY.OB), a biotechnology company, Tuesday announced new data suggesting a novel mechanism of action of leronlimab for the treatment of solid tumors.
CytoDyn analyzed data from its prior studies of patients with metastatic Triple-Negative Breast Cancer (mTNBC) and found that leronlimab treatment correlated with increased expression of an immune cell protein or checkpoint inhibitor known as programmed death-ligand 1 (PD-L1) on patients circulating tumor cells (CTCs).
Results from the analysis indicated that 88% of patients who received a weekly dose of 525 mg or higher experienced a significant increase in PD-L1 expression on their CTCs over a 30-to-90-day period after starting leronlimab. Increasing expressi...